Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Tiziana Life Sciences Ltd (TLSA)

0.9745 +0.0363 (+3.87%)
At close: 4:00:00 PM EDT
0.9745 0.0000 (0.00%)
After hours: 4:04:08 PM EDT
Chart Range Bar
Loading chart for TLSA
  • Previous Close 0.9382
  • Open 1.0500
  • Bid 1.0100 x 200
  • Ask 0.9489 x 1500
  • Day's Range 0.9500 - 1.0500
  • 52 Week Range 0.8700 - 2.3500
  • Volume 506,441
  • Avg. Volume 547,206
  • Market Cap (intraday) 124.014M
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1600
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 9.06

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

www.tizianalifesciences.com

10

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TLSA
34.60%
S&P 500 (^GSPC)
13.18%

1-Year Return

TLSA
44.31%
S&P 500 (^GSPC)
20.15%

3-Year Return

TLSA
28.22%
S&P 500 (^GSPC)
71.57%

5-Year Return

TLSA
53.15%
S&P 500 (^GSPC)
70.83%

Analyst Insights

View More

Analyst Price Targets

9.06
9.06 Average
0.9745 Current
9.06 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/3/2026
Analyst BTIG
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 7

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    124.14M

  • Enterprise Value

    120.59M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.39k

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -115.96%

  • Return on Equity (ttm)

    -924.32%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -18.43M

  • Diluted EPS (ttm)

    -0.1600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.01M

  • Total Debt/Equity (mrq)

    876.92%

  • Levered Free Cash Flow (ttm)

    -5.48M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.9745 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: